Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros

Base de datos
Tipo del documento
Intervalo de año
1.
Essays Biochem ; 65(6): 1025-1038, 2021 12 17.
Artículo en Inglés | MEDLINE | ID: covidwho-1334002

RESUMEN

COVID-19 symptoms and mortality are largely due to its devastating effects in the lungs. The disease is caused by the SARS (Severe Acute Respiratory Syndrome)-CoV-2 coronavirus, which requires host cell proteins such as ACE2 (angiotensin-converting enzyme 2) and TMPRSS2 (transmembrane serine protease 2) for infection of lung epithelia. The expression and function of the steroid hormone receptor family is important in many aspects that impact on COVID-19 effects in the lung - notably lung development and function, the immune system, and expression of TMPRSS2 and ACE2. This review provides a brief summary of current knowledge on the roles of the steroid hormone receptors [androgen receptor (AR), glucocorticoid receptor (GR), progesterone receptor (PR), mineralocorticoid receptor (MR) and oestrogen receptor (ER)] in the lung, their effects on host cell proteins that facilitate SARS-CoV-2 uptake, and provides a snapshot of current clinical trials investigating the use of steroid receptor (SR) ligands to treat COVID-19.


Asunto(s)
COVID-19/metabolismo , Pulmón/metabolismo , Pulmón/virología , Receptores de Esteroides/metabolismo , Enzima Convertidora de Angiotensina 2/metabolismo , COVID-19/virología , Femenino , Antagonistas de Hormonas/uso terapéutico , Humanos , Inmunomodulación , Masculino , Receptores Androgénicos/metabolismo , Receptores de Estrógenos/metabolismo , Receptores de Glucocorticoides/metabolismo , Receptores de Mineralocorticoides/metabolismo , Receptores de Progesterona/metabolismo , SARS-CoV-2 , Serina Endopeptidasas/metabolismo , Factores Sexuales , Tratamiento Farmacológico de COVID-19
2.
J Clin Endocrinol Metab ; 106(3): 622-635, 2021 03 08.
Artículo en Inglés | MEDLINE | ID: covidwho-949098

RESUMEN

This paper attempts to explain how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus causes the complications that make coronavirus disease 2019 (COVID-19) a serious disease in specific patient subgroups. It suggests that cortisol-associated activation of the mineralocorticoid receptor (MR) in epithelial and endothelial cells infected with the virus stimulates the release of adenosine 5'-triphosphate (ATP), which then acts back on purinergic receptors. In the lung this could produce the nonproductive cough via purinergic P2X3 receptors on vagal afferent nerves. In endothelial cells it could stimulate exocytosis of Weibel-Palade bodies (WPBs) that contain angiopoietin-2, which is important in the pathogenesis of acute respiratory distress syndrome (ARDS) by increasing capillary permeability and von Willebrand factor (VWF), which mediates platelet adhesion to the endothelium and hence clotting. Angiopoietin-2 and VWF levels both are markedly elevated in COVID-19-associated ARDS. This paper offers an explanation for the sex differences in SARS-CoV-2 complications and also for why these are strongly associated with age, race, diabetes, and body mass index. It also explains why individuals with blood group A have a higher risk of severe infection than those with blood group O. Dexamethasone has been shown to be of benefit in coronavirus ARDS patients and has been thought to act as an anti-inflammatory drug. This paper suggests that a major part of its effect may be due to suppression of cortisol secretion. There is an urgent need to trial the combination of dexamethasone and an MR antagonist such as spironolactone to more effectively block the MR and hence the exocytosis of WPBs.


Asunto(s)
Adenosina Trifosfato/metabolismo , COVID-19/complicaciones , Hidrocortisona/farmacología , Receptores de Mineralocorticoides/agonistas , Enzima Convertidora de Angiotensina 2/fisiología , Trastornos de la Coagulación Sanguínea/etiología , Trastornos de la Coagulación Sanguínea/metabolismo , Trastornos de la Coagulación Sanguínea/virología , COVID-19/metabolismo , COVID-19/patología , Dexametasona/uso terapéutico , Eplerenona/uso terapéutico , Humanos , Hidrocortisona/efectos adversos , Hidrocortisona/metabolismo , Antagonistas de Receptores de Mineralocorticoides/uso terapéutico , Modelos Biológicos , Comunicación Paracrina/efectos de los fármacos , Receptores de Mineralocorticoides/metabolismo , Receptores Purinérgicos/fisiología , Síndrome de Dificultad Respiratoria/complicaciones , Síndrome de Dificultad Respiratoria/metabolismo , Síndrome de Dificultad Respiratoria/virología , SARS-CoV-2/efectos de los fármacos , SARS-CoV-2/patogenicidad , Índice de Severidad de la Enfermedad , Espironolactona/uso terapéutico , Tratamiento Farmacológico de COVID-19
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA